Background. RAS mutations have been reported to be a potential prognostic factor in patients with colorectal liver metastases (CLM). However, the impact of RAS mutations on response to chemotherapy remains unclear. The purpose of this study was to investigate the correlation between RAS mutations and response to preoperative chemotherapy and their impact on survival in patients undergoing curative resection of CLM. Methods. RAS mutational status was assessed and its relation to morphologic response and pathologic response was investigated in 184 patients meeting inclusion criteria. Predictors of survival were assessed. The prognostic impact of RAS mutational status was then analyzed using two different multivariate models, including either radiologic morphologic response (model 1) or pathologic response (model 2). Results. Optimal morphologic response and major pathologic response were more common in patients with wildtype RAS (32.9 and 58.9 %, respectively) than in patients with RAS mutations (10.5 and 36.8 %; P = 0.006 and 0.015, respectively). Multivariate analysis confirmed that wild-type RAS was a strong predictor of optimal morphologic response [odds ratio (OR), 4.38; 95 % CI 1.45-13.15] and major pathologic response (OR, 2.61; 95 % CI 1.17-5.80). RAS mutations were independently correlated with both overall survival and recurrence freesurvival (hazard ratios, 3.57 and 2.30, respectively, in model 1, and 3.19 and 2.09, respectively, in model 2). Subanalysis revealed that RAS mutational status clearly stratified survival in patients with inadequate response to preoperative chemotherapy. Conclusions. RAS mutational status can be used to complement the current prognostic indicators for patients undergoing curative resection of CLM after preoperative modern chemotherapy.
morphologic response [odds ratio (OR), 4.38; 95 % CI 1.45-13.15] and major pathologic response (OR, 2.61; 95 % CI 1.17-5.80). RAS mutations were independently correlated with both overall survival and recurrence freesurvival (hazard ratios, 3.57 and 2.30, respectively, in model 1, and 3.19 and 2.09, respectively, in model 2). Subanalysis revealed that RAS mutational status clearly stratified survival in patients with inadequate response to preoperative chemotherapy. Conclusions. RAS mutational status can be used to complement the current prognostic indicators for patients undergoing curative resection of CLM after preoperative modern chemotherapy.
Recent advances in multidisciplinary approaches have changed the prognosis of patients with colorectal liver metastases (CLM).
1,2 As a result, traditional prognostic factors, such as disease-free interval, the number or size of CLM, and serum carcinoembryonic antigen level, have become less reliable. [3] [4] [5] [6] [7] [8] Our group has previously reported that pathologic and radiologic morphologic responses to preoperative chemotherapy are potent prognostic indicators for patients undergoing resection of CLM. [9] [10] [11] However, most patients would be classified as inadequate responders according to these criteria, with 70 % experiencing a suboptimal morphologic response and 55 % experiencing a minor pathologic response. 9, 11 Moreover, the molecular bases for these prognostic indicators remain unclear.
During the past decade, the study of somatic gene mutations has become a focus of colorectal cancer research.
has been shown to be a strong predictor of response to antiepidermal growth factor receptor (EGFR) agents. [16] [17] [18] Recent studies have suggested that KRAS mutation is a predictor of worse survival in patients undergoing resection of CLM. 19, 20 Additionally, our group previously reported that KRAS mutation is related to aggressive tumor biology. 21 However, the prognostic impact of RAS oncogene family mutation remains unclear, and little is known about the association between RAS mutational status and radiologic morphologic and pathologic responses to chemotherapy.
This study was designed to investigate associations between RAS mutations and pathologic and/or morphologic response to chemotherapy and to assess the impact of RAS mutational status on survival in patients undergoing liver resection for CLM.
PATIENTS AND METHODS

Study Population
We searched the prospectively maintained database at The University of Texas MD Anderson Cancer Center to identify patients who had undergone curative resection of CLM (without concomitant radiofrequency ablation) after a fluorouracil-based irinotecan regimen or a fluorouracil-based oxaliplatin regimen that included bevacizumab. Patients previously treated for hepatic and extrahepatic colorectal cancer metastases were excluded from our analysis, as were those who had received pre-or postoperative anti-EGFR agents, those who died within 90 days after hepatectomy, and those who had a viable tumor cell rate \5 % in their CLM specimen. This study was approved by the Institutional Review Board of the institution (PA12-0736).
Somatic Gene Mutation Profiling
DNA extracted from formalin-fixed, paraffin-embedded resected CLM was analyzed with Sequenom MassArray technology (Sequenom, Inc., San Diego, CA) using a protocol developed in our institutional core facilities. 22 Tumor position was identified on slides with standard hematoxylin-eosin staining and microdissected. A total of 17 point mutations at codons 12, 13, 61, and 146 were tested in the RAS gene family (including KRAS and NRAS). Sequenom's MassArray system utilizes polymerase chain reaction amplification and singlebase primer extension for mutation detection.
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Assessment of Radiologic Morphologic Response to Chemotherapy
Computed tomographic scans were performed using a triphasic liver protocol as previously described. 10 The radiologic morphologic response of CLM was assessed by two independent radiologists (K.H. and E.M.L.) blinded to clinical data, according to the following previously described criteria: group 1, homogeneous low attenuation with a thin, sharply defined tumor-liver interface; group 3, heterogeneous attenuation with a thick, poorly defined tumor-liver interface; and group 2, intermediate morphology that cannot be classified as either group 1 or group 3. 10, 11 Optimal radiologic morphologic response to chemotherapy was defined as a change in morphology from groups 3 or 2 to group 1. Suboptimal morphologic response was defined as a change in morphology from group 3 to group 2 or the absence of remarkable changes in morphology. In patients with multiple tumors, morphologic response was determined according to the response seen in the majority of tumors or, in patients with two CLM, in the largest one. Response to chemotherapy was also investigated according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
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Assessment of Pathologic Response to Chemotherapy
Hematoxylin-eosin-stained specimens sectioned into 5-mm-thick slices were evaluated by a gastrointestinal pathologist who was blinded to clinical data. The extent of residual carcinoma was assessed semiquantitatively as the percentage of the total tumor surface area composed of residual viable tumor cells, as previously described. Pathologic response was scored as minor if residual viable tumor cells made up C50 % of the total tumor surface area and major if residual viable tumor cells made up \50 % of the total tumor surface area. 9 
Statistical Analysis
Categorical variables were compared using the v 2 test or Fisher's exact test, and continuous variables were compared using the Mann-Whitney U test, where appropriate. Overall survival (OS) and recurrence-free survival (RFS) was measured from the date of hepatectomy using the Kaplan-Meier method. Survival differences were evaluated with the log-rank test.
To identify prognostic factors for RFS and OS, the following 12 variables were assessed in univariate analysis: disease-free interval between primary tumor and CLM diagnosis, primary tumor location (colon vs rectum), primary tumor nodal status, presence of extrahepatic metastases, number of preoperative chemotherapy cycles, number and diameter of CLM at surgery, positive surgical margin, RECIST response [partial response (PR) vs. stable disease (SD) or progressive disease (PD)], pathologic and morphologic response to chemotherapy, and RAS mutational status. All variables included in the univariate analysis (except pathologic response in model 1 and morphologic response in model 2) were subsequently included in a multivariate regression analysis, performed using the Cox proportional hazards model with backward elimination for variables with P \ 0.1. Given the strong colinearity between pathologic and morphologic responses to chemotherapy, prognostic factors influencing survival were analyzed using two different multivariate models that included either pathologic response (model 1) or morphologic response (model 2). 10, 11 To identify factors associated with optimal morphologic or major pathologic response, eight preoperative factors were analysed in univariate analysis: disease-free interval between primary tumor and CLM diagnosis, primary tumor location, primary tumor nodal status, presence of extrahepatic metastases, number of preoperative chemotherapy cycles, number and diameter of CLM at diagnosis, RE-CIST response, and RAS mutational status. A multivariate analysis was performed using the logistic regression model for clinical variables with P \ 0.1 in univariate analysis. Statistical analyses were performed using IBM SPSS software (version 19.0; SPSS Inc., Chicago, IL). All statistical tests were two-sided, and significance was set at P \ 0.05.
RESULTS
Patient Characteristics and Comparison of Patients according to RAS Mutational Status
Of the 308 patients initially eligible for this study, we excluded 36 patients who lacked tissue samples for DNA extraction due to complete pathologic response, 30 patients whose DNA samples were of insufficient quality for Sequenom analysis, and 58 patients whose computed tomographic images were of insufficient quality or whose lesions were too small (\10 mm after preoperative chemotherapy) for morphologic response to be determined.
Baseline characteristics of the remaining 184 patients included in the current study are summarized in Table 1 . RAS mutations were seen in 38 patients (21 % of the population; 32 had KRAS mutation and 6 had NRAS mutation). RECIST criteria demonstrated that 81 patients (44 %) were classified as PR, and the remaining 103 (56 %) were classified as SD or PD.
Predictors of Pathologic and Morphologic Response to Chemotherapy
Optimal morphologic response was observed in 52 of the 184 patients (28 %), and major pathologic response was observed in 100 patients (54 %). Tumor cell viability differed according to morphologic response [median viability, 30 % (range 5-70 %) in patients with optimal response vs. 50 % (range 5-90 %) in patients with suboptimal response (P \ 0.001)]. Optimal morphologic response and major pathologic response were more Table 2 ). When classifying patients according to percentage of viable tumor cells, RAS mutation rate decreased as the percentage of viable tumor cells declined. RAS mutation rate was 33 % in patients with more than 80 % viable cells, whereas the mutation rate was 13 % in those with 5-20 % viable cells (P = 0.021; Fig. 1 ).
Risk Factors for Decreased OS and RFS
Multivariate analysis showed that independent predictors of decreased OS were RAS mutation [hazard ratio (HR), 3.25; CI 1.80-5.87; P \ 0.001], minor pathologic response (HR, 1.78; CI 1.05-3.03; P = 0.033), and having undergone [6 preoperative chemotherapy cycles (HR, 1.70; CI, 1.01-286; P = 0.044) in model 1, and RAS mutation (HR, 3.19; CI 1.75-5.78; P \ 0.001), suboptimal morphologic response (HR, 2.32; CI 1.09-4.97; P = 0.029), and positive nodal status for the primary tumor (HR, 1.95; CI 1.01-3.81; P = 0.049) in model 2. Multivariate analysis for RFS revealed that independent predictors of decreased RFS were RAS mutation (HR, 1.86; CI 1.17-2.96; P = 0.008), having undergone [6 chemotherapy cycles (HR, 1.49; CI 1.01-2.18; P = 0.040), and minor pathologic response (HR: 1.85; CI 1.25-2.74; P = 0.002) in model 1, and RAS mutation (HR, 2.09; CI 1.32-3.30; P \ 0.001) and suboptimal morphologic response (HR, 1.83; CI 1.16-2.87; P = 0.009) in model 2.
Survival Outcomes
After a median follow-up of 33 months, 64 patients had died, 40 were alive with disease recurrence, and 80 were alive with no evidence of disease at last follow-up. OS rates for the entire cohort were 72.6 % at 3 years and 52.4 % at 5 years. The 5-year OS rate was higher for patients with major pathologic response (64.2 %) than for those with minor pathologic response (44.6 %; P = 0.005; Fig. 2a ), higher for patients with optimal morphologic response (72.9 %) than for those with suboptimal morphologic response (42.9 %; P = 0.007; Fig. 2c) , and higher for patients with wild-type RAS (61.6 %) than for those with RAS mutation (23.2 %; P \ 0.001). Likewise, the 5-year RFS rate was higher for patients with major pathologic response (35.8 %) than for those with minor pathologic response (16.5 %; P \ 0.001), higher for patients with optimal morphologic response (39.8 %) than for those with suboptimal morphologic response (22.2 %; P = 0.002), and higher for patients with wild-type RAS (31.7 %) than for those with RAS mutation (NA; P \ 0.001).
Additional subanalysis revealed that among patients with minor pathologic response (Fig. 2b) , patients with RAS mutation had a significantly worse 3-year OS rate than patients with wild-type RAS (30.9 vs. 72.3 %; P \ 0.001). Similarly, among patients with suboptimal morphologic response (Fig. 2d) , patients with RAS mutation had a significantly worse 3-year OS rate than patients with wildtype RAS (41.8 vs. 76.8 %; P \ 0.001).
DISCUSSION
In this study, RAS mutational status independently predicted both morphologic response and pathologic response in 184 patients who underwent curative resection after receiving a fluorouracil-based irinotecan regimen or a fluorouracil-based oxaliplatin. RAS mutational status also independently predicted both OS and RFS, and further subanalysis revealed that RAS mutational status stratified survival outcomes in patients with suboptimal morphologic response or minor pathologic response to chemotherapy.
In the era of modern chemotherapy, pathologic and morphologic response have been proposed as new endpoints to predict long-term outcomes in patients undergoing resection of CLM after chemotherapy. [9] [10] [11] 27, 28 However, these response criteria can be used only after chemotherapy, and the molecular bases for differences in susceptibility to chemotherapy remain unclear. RAS mutation is a well-known predictor of lack of response to anti-EGFR agents in both patients with advanced metastatic colorectal cancer and patients with metastases limited to the liver. 16, 18, 29 Additionally, a growing body of evidence suggests that the RAS mutational status of CLM might be associated with tumor aggressiveness. [19] [20] [21] 30 In this study, optimal morphologic response was less common in patients with RAS mutation (10.5 %) than those with wild-type RAS (32.9 %). Likewise, major pathologic response was less common in patients with RAS mutation (36.8 %) than in those with wild-type RAS (56.8 %). As confirmed in the present study, there was an association between RAS mutation rate and percentage of viable tumor cells after preoperative chemotherapy. These results suggest that RAS mutational status predicts patterns of pathologic and morphologic response to chemotherapy.
Moreover, RAS mutational status was found to be an independent predictor of both OS and RFS, further stratifying survival in patients with minor pathologic and suboptimal morphologic response (Fig. 2) . On the other hand, conventional RECIST criteria did not predict survival, which is in line with recent studies showing that sizebased radiologic criteria have diminished the accuracy to predict response to targeted therapy in patients with CLM. 10, 11, 31, 32 The current data, if confirmed in larger studies, could be used to predict clinical outcomes, not only after resection but also when resection is being considered. Among patients with multiple ill-located metastases necessitating extended, risky resections, a combination of radiologic response of CLM and RAS mutational status (determined by analyzing the primary tumor or by using biopsy specimens from the primary tumor or CLM) could help to select patients who might benefit from a more aggressive surgical approach. While patients with a combination of suboptimal morphologic response and RAS mutation generally should be considered candidates for liver resection if negative margins can be reasonably expected, the same patients should be considered more cautiously for complex hepatectomy, because the risk related to extensive hepatectomy may outweigh the limited potential survival benefit (Fig. 3) .
One criticism of this study is that RAS mutational status was determined on resected CLM and not on the primary tumor and that the two tumor sites might differ in mutational status. However, a growing body of evidence suggests a high rate of concordance in somatic gene mutational status between primary tumor and related metastases, strengthening the validity of our results. [33] [34] [35] [36] [37] Other potential criticisms of this study include its retrospective nature and the selected population. Although this study was conducted using data from a prospectively constructed database of patients undergoing resection of CLM, a number of patients were excluded from the initial population because of a lack of sufficient tumor for DNA extraction and Sequenom analysis. However, even after exclusion of patients with extremely good pathologic response to chemotherapy, morphologic and pathologic response independently predicted survival, consistent with results from previous studies based on large cohorts of patients. 9, 11 Moreover, RAS mutational status remained a powerful prognostic factor. Although OS may have been affected by anti-EGFR therapy after recurrence, the impact of RAS status on RFS suggests that anti-EGFR therapy has a minimal confounding effect.
In conclusion, we investigated the genetic backgrounds affecting pathologic response and morphologic response in patients treated with modern chemotherapy and found that RAS mutational status is associated with both morphologic and pathologic response to chemotherapy. RAS mutations, pathologic response, and morphologic response independently predict survival outcomes in patients undergoing resection of CLM after preoperative chemotherapy. RAS mutations clearly stratify survival outcomes in patients with inadequate response to chemotherapy. Finally, RAS mutational status should be used as a complementary molecular marker of response to chemotherapy and of prognosis both before and after preoperative chemotherapy e Optimal morphologic response after 3 months of preoperative FOLFOX with bevacizumab. f Major pathologic response (\10 % viable tumor cells in CLM) after resection. As of this writing, the patient is alive and disease-free more than 6 years after extended right hepatectomy for CLM. Wild-type RAS status may encourage some surgeons to pursue resection in patients with borderline resectable disease and suboptimal response to chemotherapy. As such, the current results may contribute to personalized care in the treatment of CLM.
